Many to benefit from £2-a-day anti-clotting drug

Many to benefit from £2-a-day anti-clotting drug preventing heart attacks and strokes The draft guidance for ticagrelor for reducing the risk of cardiovascular events in people who have had a heart attack NICE has published draft guidance recommending anti-clotting drug ticagrelor 60 mg (Brilique, Astrazeneca) with aspirin for people who have had a heart attack.…

Read More

Recommendation of secukinumab for patients with ankylosing spondylitis In draft guidance NICE,England and Wales,recommends innovative new drug secukinumab (Cosentyx, Novartis) for treating ankylosing spondylitis. Ankylosing spondylitis is a type of arthritis that mainly affects the back. Secukinumab was licensed for use in UK in May, is first in a new class of drug to treat…

Read More

Improved breast cancer treatments

Breast cancer improvement – an updated quality standard England and Wales People diagnosed with a type of early breast cancer and at risk of the cancer spreading should be offered an Oncotype DX test. This test provides information about genetic makeup of the tumour to help predict its development. This information can be used to…

Read More

New tests for pregnancy complication to avoid hospital admission

NHS England and Wales: Nice recommendations on new tests to rule out pregnancy  complication and avoid unnecessary hospital admission. In a final guidance, a recommendation for 2 blood tests to help rule-out pre-eclampsia, a potentially life threatening complication affecting as many as one in 16 pregnant women1.NICE recommends the Triage PlGF test (Alere) and the…

Read More

Treatment recommendation: advanced skin cancer

Treatment recommendation for advanced skin cancer Advanced (unresectable or metastatic) melanoma. 18 Feb 2016 NICE final guidance recommending nivolumab as monotherapy for treating advanced skin cancer.  Nivolumab called Opdivo, and manufactured by Bristol Myers Squibb is to be made available on the NHS as a  treatment option for patients with advanced unresectable or metastatic melanoma.…

Read More

Advanced skin cancer guidance

Advanced skin cancer guidance Final draft guidance recommends nivolumab for advanced skin cancer The National Institute for Health and Care Excellence (NICE) England, on Friday 22 January said yes to nivolumab as monotherapy for treating advanced skin cancer in final draft guidance. ….more

Read More

New common heart condition drug tested

PRESS RELEASE Innovative drug for common heart condition (England) NICE is provisionally recommending novel heart failure drug sacubitril valsartan (Novartis) as an option for some people with heart failure. This guidance recommends the drug for treating chronic heart failure with reduced ejection fraction[i] in people with New York Heart Association class II to III symptoms[ii]…

Read More
UK flag as shield

uk: Treat moderate to severely active ulcerative colitis

Treatment  recommendation: To treat moderate to severely active ulcerative colitis a final guidance was published recommending vedolizumab (Entyvio, Takeda) Vedolizumab provides a further treatment option when conventional therapy or TNF-alpha inhibitors either don’t work well, has stopped working or can’t be tolerated. Vedolizumab is recommended on basis it is provided to the NHS at a…

Read More